Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

被引：0

作者：

Amoozgar, Behzad ^{[1
]}

Bangolo, Ayrton, I ^{[2
]}

Uesole, David H. ^{[3
,4
]}

Siegel, David S. ^{[5
,6
]}

Biran, Noa ^{[3
]}

Phull, Pooja ^{[3
]}

Donato, Michele L. ^{[7
]}

Parmar, Harsh ^{[3
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA

[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA

[4] Medstar GeorgetownMed Ctr, Lombardi Comprehens Canc Ctr, Washington, DC USA

[5] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA

[6] Ctr Discovery & Innovat, Hackensack, NJ USA

[7] Hackensack Meridian Hlth, John Theurer Canc Ctr, Stem Cell Transplantat & Cellular Therapy Program, Hackensack, NJ USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-211671

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2408 / 2409

页数：2

共 50 条

[21] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience
Hansen, Doris
Sidana, Surbhi
Peres, Lauren
Leitzinger, Christelle Colin
Shune, Leyla
Shrewsbury, Alexandria
Gonzalez, Rebecca
Sborov, Douglas
Wagner, Charlotte
Hashmi, Hamza
Kocoglu, Mehmet
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher
Afrough, Aimaz
Kansagra, Ankit
Voorhees, Peter
Baz, Rachid
Khouri, Jack
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick
Patel, Krina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S2 - S3
[22] Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, Joao
Hernando, Teresa
Burnett, Heather
Cost, Patricia
Schecter, Jordan M.
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Er, Jeremy
Harrison, Simon J.
Lopez-Munoz, Nieves
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (09) : 1597 - 1603
[23] Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Lopez-Munoz, Nieves
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, Joao
Lee, Seina
Hernando, Teresa
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Er, Jeremy
Harrison, Simon J.
Shah, Urvi A.
BLOOD, 2024, 144 : 3390 - 3391
[24] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
Dima, Danai
Davis, James A.
Ahmed, Nausheen
Jia, Xuefei
Sannareddy, Aishwarya
Shaikh, Hira
Shune, Leyla
Kaur, Gurbakhash
Khouri, Jack
Afrough, Aimaz
Strouse, Christopher
Lochner, Jonathan
Mahmoudjafari, Zahra
Raza, Shahzad
Valent, Jason
Anderson Jr, Larry D.
Anwer, Faiz
Abdallah, Al-Ola
Hashmi, Hamza
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
[25] A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
Dileo, Rachel
Mewawalla, Prerna
Babu, Kalaivani
Yin, Yue
Strouse, Christopher
Chen, Ethan
Shaikh, Hira
Davis, James A.
Green, Kimberly M.
Alkharabsheh, Omar
Rashid, Aliya
Pokhrel, Bidushi
Ahmed, Nausheen
Abdallah, Al-Ola
Hashmi, Hamza
BLOOD CANCER JOURNAL, 2025, 15 (01):
[26] Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, Joao
Hernando, Teresa
Cost, Patricia
Schecter, Jordan M.
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Jeremy, E. R.
Harrison, Simon J.
Lopez-Munoz, Nieves
BLOOD, 2023, 142
[27] Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Hansen, Doris K.
Patel, Krina K.
Peres, Lauren C.
Kocoglu, Mehmet H.
Shune, Leyla
Simmons, Gary
Ferreri, Christopher J.
Atrash, Shebli
Parrondo, Ricardo Daniel
Chhabra, Saurabh
Costello, Patrick
Midha, Shonali
Alsina, Melissa
Voorhees, Peter M.
Htut, Myo
Sborov, Douglas W.
Khouri, Jack
Janakiram, Murali
Lin, Yi
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up
Sidana, Surbhi
Patel, Krina
Peres, Lauren
Bansal, Radhika
Kocoglu, Mehmet
Atrash, Shebli
Dima, Danai
Smith, Kinaya
Ferreri, Christopher
Midha, Shonali
Dhakal, Binod
Herr, Megan
Nadeem, Omar
Reshef, Ran
Kumar, Anupama
Mann, Hashim
Kalariya, Nilesh
Sborov, Douglas W.
Richard, Shambavi
Khouri, Jack
Martin, Thomas
Htut, Myo
Shune, Leyla
Lin, Yi
Hansen, Doris
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S7 - S8
[29] Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Martin, Tom
Usmani, Saad Z.
Schecter, Jordan M.
Roccia, Tito
Jackson, Carolyn C.
Deraedt, William
Yeh, Tzu-Min
Banerjee, Arnob
Pacaud, Lida
Garrett, Ashraf
Bartlett, Meaghan
Haltner, Anja
Van Sanden, Suzy
Diels, Joris
Valluri, Satish
Samjoo, Imtiaz A.
CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (01) : 81 - 89
[30] Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium
Wagner, Charlotte B.
Sweiss, Karen
Anto, Eric
Gonzalez, Rebecca
Puglianini, Omar Alexis Castaneda
Freeman, Ciara Louise L.
Ionescu, Filip
Patel, Krina K.
Ferreri, Christopher
Gaballa, Mahmoud
Shune, Leyla
McGuirk, Joseph P.
Sidana, Surbhi
Hovanky, Vanna
Khouri, Jack
Dima, Danai
Hashmi, Hamza
Davis, James A.
Afrough, Aimaz
Kaur, Gurbakhash
Larry, Anderson D., Jr.
Forsberg, Peter A.
Herr, Megan
Hansen, Doris K.
Sborov, Douglas
Kocoglu, Mehmet H.
BLOOD, 2023, 142

← 1 2 3 4 5 →